Abstract
Background Social anxiety disorder is a common mental health condition characterized by an intense fear of social situations which can lead to significant impairment in daily life. Cognitive behavioral therapy (CBT) has been recognized as an effective treatment; however, access to therapists is limited and the fear of interacting with therapists can delay treatment seeking. Furthermore, not all individuals respond. Tailoring modular treatments to individual cognitive profiles may improve efficacy. We developed a novel digital adaptation of CBT for social anxiety that is both modular and fully digital without therapist in the loop and implemented it in a smartphone app.
Objective To evaluate the safety, acceptability and efficacy of the new treatment in online participants with symptoms of social anxiety
Methods Two online randomized controlled trials comparing individuals with access to the treatment through the app to waitlist. Participants were recruited online and reported Social Phobia Inventory (SPIN) total scores >= 30. Primary outcomes were safety and efficacy over 6 weeks in 102 women aged 18-35 (RCT #1) and symptom reduction (Social Phobia Inventory total scores) after 8 weeks in 267 men and women aged 18-75 (RCT #2).
Results In RCT #1, active and control arm adverse event frequency and severity was not distinguishable. App acceptability was high. Secondary outcomes suggested greater symptom reduction in the active (-9.83 ± 12.80) than the control arm (-4.13 ± 11.59, t90 = -2.23, pFDR = .037, Cohen’s d = 0.47). In RCT #2, there was a higher symptom reduction in the active arm (-12.89 ± 13.87) than the control arm (-7.48 ± 12.24, t227 = - 3.13, pFDR = .008, Cohen’s d = 0.42).
Conclusions The online-only, modular social anxiety CBT program appears safe, acceptable and efficacious in an online patient group with self-reported symptoms of social anxiety.
Trial Registration RCT #1: ClinicalTrials.gov NCT05858294, RCT #2: ClinicalTrials.gov NCT05987969
Competing Interest Statement
This study was sponsored and funded in full by Alena (Aya Technologies Ltd). Study authors MMG, JM, TM, SSM, SS, PS and AL were employed by Alena at the time of conducting the study and SL was paid on a consultancy basis. MMG, JM, SSM, SS, AL and MA own share options. QJMH is employed by University College London and acknowledges research grant funding from the Wellcome Trust, Carigest S.A. and Koa Health, and fees and share options for consultancies for Aya Technologies Ltd and Alto Neuroscience.
Clinical Trial
NCT05858294, NCT05987969
Funding Statement
This study was sponsored and funded in full by Alena (Aya Technologies Ltd).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Reading Independent Ethics Committee gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data is not available.
Abbreviations
- AUDIT-C
- Alcohol Use Disorders Identification Test for Consumption
- BF01
- Bayes Factor for the Null Hypothesis
- CBT
- Cognitive Behavioral Therapy
- GP
- General Practitioner
- iCBT
- Internet-delivered Cognitive Behavioral Therapy
- ISO
- International Organization for Standardization
- NHS
- National Health Service
- RCT
- Randomized Controlled Trial
- SAD
- Social Anxiety Disorder
- SD
- Standard Deviation
- SPIN
- Social Phobia Inventory
- UCL
- University College London
- WSAS
- Work and Social Adjustment Scale
